These findings suggest that enhancing autophagy through mTOR inhibition may be beneficial only when lysosomal function is intact, highlighting the need for patient-specific or stage-specific approaches in potential AD treatments [29]. The gene discussed is MTOR; the disease is Alzheimer disease.